

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



The United Laboratories International Holdings Limited

聯邦制藥國際控股有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 3933)

UPDATED INFORMATION ON THE GROUP'S PRODUCT IBUPROFEN SUSTAINED-RELEASE CAPSULES

This announcement is made by The United Laboratories International Holdings Limited (the "Company") on a voluntary basis.

The board of directors (the "Board") of the Company is pleased to announce that the Ibuprofen Sustained Release Capsules (specification: 0.3g) submitted by Zhuhai United Laboratories Co., Ltd, Zhongshan Branch, a wholly-owned subsidiary of the Company, with the approval of the National Medical Products Administration, passed the consistency evaluation of quality and efficacy for generic drugs ("Consistency Evaluation").

Ibuprofen sustained-release capsules are antipyretic, analgesic and non-steroidal anti-inflammatory drugs, classified as Category A over-the-counter (OTC) drugs. The drug is used to relieve mild to moderate pain such as headache, joint pain, migraine, toothache, muscle pain, neuralgia, dysmenorrhea, and fever caused by the common cold or influenza. At present, the product has been listed in the National Essential Drug List (2018 version) and Category B in the National Medical Insurance Drug List (2022 version). Ibuprofen is internationally recognized as one of the safest and most effective antipyretic drugs and one of the world's best-selling non-steroidal anti-inflammatory drugs.

This approval will further enhance the brand value of the Group's products as well as the market competitiveness. The Company will continue to devote itself to the research and development of new products and the promotion of the Consistency Evaluation, which is expected to create greater values for the Company and its shareholders.

By Order of the Board

The United Laboratories International Holdings Limited

Tsoi Hoi Shan

Chairman

Hong Kong, 6 September 2023

As at the date of this announcement, the Board comprises Mr. Tsoi Hoi Shan, Mr. Leung Wing Hon, Ms. Choy Siu Chit, Mr. Fang Yu Ping, Ms. Zou Xian Hong and Ms. Zhu Su Yan as executive directors; and Mr. Chong Peng Oon, Prof. Song Ming and Dr. Fu Qiushi as independent non-executive directors.